GlassScriptPhysician profile
Robert Stephen Kelleher
NPI 1144643404
$1,896.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2022: $660 · 2023: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $326.32 | 2021-2022 | |
| Advanced Respiratory, INC | $206.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $199.67 | 2022 | |
| United Therapeutics Corporation | $187.76 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.32 | 2021-2023 | |
| Genzyme Corporation | $144.13 | 2021-2022 | |
| Baxter Healthcare | $142.46 | 2022 | |
| Abbvie INC. | $124.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.07 | 2021 | |
| Genentech USA, INC. | $90.60 | 2021-2022 | |
| Glaxosmithkline, LLC. | $52.21 | 2021-2022 | |
| Mylan Specialty L.P. | $46.67 | 2021-2022 | |
| Grifols USA, LLC | $41.06 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kelleher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.